TY - JOUR
T1 - Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms
T2 - From bench to bedside
AU - Cella, Chiara Alessandra
AU - Minucci, Saverio
AU - Spada, Francesca
AU - Galdy, Salvatore
AU - Elgendy, Mohamed
AU - Ravenda, Paola Simona
AU - Zampino, Maria Giulia
AU - Murgioni, Sabina
AU - Fazio, Nicola
PY - 2015/11/1
Y1 - 2015/11/1
N2 - After years of limited progress in the treatment of neuroendocrine neoplasms (NENs), an increasing number of therapeutic targets have recently emerged as potential tools to improve disease outcome. The mammalian target of rapamycin (mTOR) pathway and vascular endothelial growth factor (VEGF) signalling are implicated in the regulation of cell growth, proliferation, neo-angiogenesis and tumour cell spread. Their combined blockade, in a simultaneous or sequential strategy, represents an intriguing biological rationale to overcome the onset of resistance mechanisms. However, is becoming increasingly imperative to find the optimal sequential strategy according to the best toxicity profile, and also to identify predictive biomarkers. We will provide an overview of the pre-clinical and clinical data relating to mTOR pathway/VEGF signalling as a potential targets of treatment in NENs.
AB - After years of limited progress in the treatment of neuroendocrine neoplasms (NENs), an increasing number of therapeutic targets have recently emerged as potential tools to improve disease outcome. The mammalian target of rapamycin (mTOR) pathway and vascular endothelial growth factor (VEGF) signalling are implicated in the regulation of cell growth, proliferation, neo-angiogenesis and tumour cell spread. Their combined blockade, in a simultaneous or sequential strategy, represents an intriguing biological rationale to overcome the onset of resistance mechanisms. However, is becoming increasingly imperative to find the optimal sequential strategy according to the best toxicity profile, and also to identify predictive biomarkers. We will provide an overview of the pre-clinical and clinical data relating to mTOR pathway/VEGF signalling as a potential targets of treatment in NENs.
KW - Dual inhibition
KW - Hypoxia
KW - MTOR pathway
KW - Neuroendocrine tumours
KW - VEGF signalling
UR - http://www.scopus.com/inward/record.url?scp=84945436714&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945436714&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2015.06.008
DO - 10.1016/j.ctrv.2015.06.008
M3 - Article
C2 - 26142874
AN - SCOPUS:84945436714
VL - 41
SP - 754
EP - 760
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
SN - 0305-7372
IS - 9
ER -